Growing weapons to fight hemophilia
Copyright policy )Growing weapons to fight hemophilia
Very few rare diseases have witnessed the gigantic progress in patient care that took place for the hemophilias in the last 20 years. The first landmark was in the 1990s, when recombinant DNA technology afforded the industrial production, regulatory approval and commercialization of an array of factor VIII (FVIII) and factor IX (FIX) products, potentially available in unlimited quantity, efficacious and free from the risk of transmission of such bloodborne infections as HIV and the hepatitis virus B and C [...].
plasma half-life, rFVIII, hemophilia, RC666-701, recombinant prophylactic therapy, efanesoctocog, Diseases of the circulatory (Cardiovascular) system
plasma half-life, rFVIII, hemophilia, RC666-701, recombinant prophylactic therapy, efanesoctocog, Diseases of the circulatory (Cardiovascular) system
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).1 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!